Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

SEATTLE, Aug. 11 /PRNewswire/ -- Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.

Omeros' Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of Omeros' product candidate added to a standard surgical irrigation solution. The data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control. There were no serious adverse events and no discontinuations due to adverse events.

This Phase 1/Phase 2 clinical trial was a parallel-group, double-blind, vehicle-controlled study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. The trial included three arms of equal size. In the first arm, OMS302 including both the mydriatic and anti-inflammatory agents was added to a standard irrigation solution used in ophthalmologic surgery and delivered directly to the eye during the operation. In the second arm, patients received irrigation solution including only the mydriatic agent, and in the third arm, patients received standard irrigation solution only. For efficacy assessments, patients were monitored for pupil size during surgery and for pain and inflammation for 14 days following surgery.

"We are pleased with the results of this study, which suggest that OMS302 would be useful in helping maintain mydriasis throughout cataract surgery a
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... data solutions driven by Semantic Web technology, and ... specialist information and services for the academic and ... that its joint solution ‘Smart Data Lake for ... finalist for the 2015 Bio-IT ‘Best of Show’ ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased ... for the 2015 BIO International Convention. Hosted by ... Convention will take place June 15-18 at the Pennsylvania ... BIO contest, industry leaders will be voting for companies ... The community voting period began on April 14, 2015 ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 According ... overexertion involving an outside source was ranked first ... includes injuries related to lifting, pushing, pulling, holding, ... in direct costs. The David Round Company takes ... committed to working hard to develop and design ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... is known for its innovation and ability to take ... changing the dynamics and places like South Korea, China ... too. India, for example, is gaining ground in software ... that we hear so much about. The advantages the ...
... an idea of the intricacy possible in machining and tool ... EDM, you can tunnel into the thin side of a ... and leave the top and lower surfaces of that same ... used by Steve Plendl, the lead EDM instructor at ...
... exploring new technologies that will result in a more ... Systems based in Menasha, Wisconsin is strategically investing ... of care it offers by focusing on those initiatives ... ,Affinity has been able to prioritize such investments as ...
Cached Biology Technology:Keeping Innovation Vibrant in the U.S. 2Powerful, Intricate Technology Taught in CVTCs New Tool and Die Program 2Powerful, Intricate Technology Taught in CVTCs New Tool and Die Program 3Affinity Health Streamlines IT Governance 2
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... will host its 2014 Biodefense and Emerging Diseases Research ... Hotel in Washington, DC. The purpose of this ... out research to defend against the threat of bioterrorism ... recognizing that emerging infectious diseases serve as a paradigm ...
... RNA is not merely a transitional state between DNA and ... how genes are turned into a protein product. Gaining a ... on diseases that arise when this function goes awry. ... up to offer a new method for elucidating RNA regulation. ...
... deadly form of primary malignant brain cancer accounting for ... in adults between the ages of 45 and 70. ... only temporarily contained by combined surgery, chemotherapy and radiation ... in an average patient survival time of less than ...
Cached Biology News:Penn biologists establish new method for studying RNA's regulatory 'footprint' 2Penn biologists establish new method for studying RNA's regulatory 'footprint' 3Stopping tumors in their path 2
...
...
... data entry by collecting data from any ... Collect is extremely easy to use ... data entry. An excellent solution for ... spectrophotometers, force gauges, digital calipers, bar code ...
... the autofluorescent pigment lipofuscin accumulates in ... including neurons. The presence of lipofuscin ... fluorescence microscopy in the central nervous ... and emission spectra, which overlaps with ...
Biology Products: